Why the study?
Intermediate hs-cTnI concentrations are associated with coronary atherosclerosis and MACEs, but the clinical utility of CCTA in suspected ACS patients ruled out for MI with intermediate hs-cTnI in the ED required evaluation.
Does coronary computed tomography angiography (CCTA) improve diagnostic clarity and clinical outcomes in suspected ACS patients ruled out for MI with intermediate hs-cTnI concentrations?
Does coronary computed tomography angiography (CCTA) improve diagnostic clarity and clinical outcomes in suspected ACS patients ruled out for MI with intermediate hs-cTnI concentrations?
In suspected ACS patients with intermediate hs-cTnI, CCTA offers diagnostic clarity and reduces the need for invasive procedures without compromising 1-year clinical outcomes.
CCTA may aid risk stratification in ED patients with intermediate hs-cTnI ruled out for MI; leaves open prospective outcome trials.
Background: percentile (34 ng/L for males and 16 ng/L for females), are associated with an increased prevalence and severity of coronary atherosclerosis, as well as a high risk of major adverse cardiac events (MACEs). This study aimed to evaluate the clinical utility of coronary computed tomography angiography (CCTA) in suspected ACS patients who are ruled out for myocardial infarction (MI) and have intermediate hs-cTnI concentrations in the emergency department (ED). Methods: The retrospective longitudinal cohort study investigated two independent cohorts of 3,657 suspected ACS patients from November 2017 to January 2019. Eligible patients with intermediate hs-cTnI were divided into two groups: the CCTA group and the no-CCTA group (patients who underwent CCTA and those who did not, respectively). In both groups, patients were matched at a 1:3 ratio within a caliper of 0.05 using propensity score matching (PSM). Results: . 35 (8.7%) in no-CCTA group; P=0.96]. Specifically, CCTA provided clear differential diagnoses for 19% (26/136) of patients with non-obstructive coronary artery disease (CAD). Conclusions: In suspected ACS patients ruled out for MI and with intermediate hs-cTnI concentrations, CCTA offers diagnostic clarity and reduces the need for invasive procedures without affecting 1-year clinical outcomes.
No takes yet. Share an insight, caveat, or question.
Ma et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: